Literature DB >> 12168103

The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors.

Peter R Lindgren1, T Bäckström, S Cajander, M-G Damber, C-G Mählck, D Zhu, J I Olofsson.   

Abstract

Epidemiological studies have indicated a relationship between gonadal steroid hormones and ovarian cancer. A production of both estradiol and progesterone by ovarian cancers has been demonstrated. The local steroid concentrations and the putative relation to histopathological and clinical condition were investigated herein. Ovarian tissue, ovarian tumor cyst fluid, ovarian vein samples and peripheral serum concentrations of estradiol and progesterone in pre- and post-menopausal women, subdivided into groups with normal ovaries, benign, borderline and malignant ovarian tumors, were quantitatively assessed. Both ovarian tissue concentrations of estradiol and progesterone were more than 100-fold higher than in serum. Based on differences in concentrations between different ovarian tumor groups, the data is not coherent with the previously suggested increased production of estradiol and progesterone in ovarian cancer tissue, since post-menopausal women with ovarian cancer presented lower median tissue hormone levels, most pronounced between malignant and benign tumors; median (25 and 75 percentile) estradiol; 9.40 (6.67-15.50) vs 16.44 (12.49-23.20), p=0.02 and progesterone; 308 (240-575) vs 957 (553-1143) pmol/g wet weight, p<0.01, n=81. Lower concentrations of estradiol, but not progesterone, were found in ovarian cancer tissue, ovarian cyst fluid and peripheral serum in patients with FIGO stages 3 and 4 than in stages 1 and 2. The novel finding of a large ovarian tissue to serum difference of both estradiol and progesterone indicates an important role of ovarian tissue concentrations in tumor biology and raises the question of adequate doses of anti-hormonal therapy in women with ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168103

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  Immunohistochemical analysis of 17β-hydroxysteroid dehydrogenase isozymes in human ovarian surface epithelium and epithelial ovarian carcinoma.

Authors:  Ken-ichi Motohara; Hironori Tashiro; Yumiko Taura; Takashi Ohba; Hidetaka Katabuchi
Journal:  Med Mol Morphol       Date:  2011-01-26       Impact factor: 2.309

Review 2.  Emerging significance of ER-coregulator PELP1/MNAR in cancer.

Authors:  S Nair; R K Vadlamudi
Journal:  Histol Histopathol       Date:  2007-01       Impact factor: 2.303

3.  miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.

Authors:  Yulei Wei; Hong Li; Quanxin Qu
Journal:  Breast Cancer       Date:  2020-08-31       Impact factor: 4.239

4.  Estrous cycle modulates ovarian carcinoma growth.

Authors:  Guillermo N Armaiz-Pena; Lingegowda S Mangala; Whitney A Spannuth; Yvonne G Lin; Nicholas B Jennings; Alpa M Nick; Robert R Langley; Rosemarie Schmandt; Susan K Lutgendorf; Steven W Cole; Anil K Sood
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

5.  Methoxychlor and estradiol induce oxidative stress DNA damage in the mouse ovarian surface epithelium.

Authors:  Daniel A Symonds; Istvan Merchenthaler; Jodi A Flaws
Journal:  Toxicol Sci       Date:  2008-05-22       Impact factor: 4.849

6.  Apelin abrogates the stimulatory effects of 17β-estradiol and insulin-like growth factor-1 on proliferation of epithelial and granulosa ovarian cancer cell lines via crosstalk between APLNR and ERα/IGF1R.

Authors:  Marta Hoffmann; Justyna Gogola; Anna Ptak
Journal:  Mol Biol Rep       Date:  2019-09-20       Impact factor: 2.316

7.  BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability.

Authors:  Kienan I Savage; Kyle B Matchett; Eliana M Barros; Kevin M Cooper; Gareth W Irwin; Julia J Gorski; Katy S Orr; Jekaterina Vohhodina; Joy N Kavanagh; Angelina F Madden; Alexander Powell; Lorenzo Manti; Simon S McDade; Ben Ho Park; Kevin M Prise; Stuart A McIntosh; Manuel Salto-Tellez; Derek J Richard; Christopher T Elliott; D Paul Harkin
Journal:  Cancer Res       Date:  2014-03-17       Impact factor: 12.701

8.  The effect of talc particles on phagocytes in co-culture with ovarian cancer cells.

Authors:  Angelo Mandarino; David J Gregory; Connor C McGuire; Brian W Leblanc; Hadley Witt; Loreilys Mejias Rivera; John J Godleski; Alexey V Fedulov
Journal:  Environ Res       Date:  2019-08-22       Impact factor: 6.498

9.  BRCA-1 and BRCA-2 mutation bedside detection and breast cancer clinical primary prevention.

Authors:  Sergio Stagnaro; Simone Caramel
Journal:  Front Genet       Date:  2013-03-26       Impact factor: 4.599

Review 10.  Estrogen, progesterone and epithelial ovarian cancer.

Authors:  Shuk-Mei Ho
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.